动物实验,血清代谢 z-bo 2020-10-12 345

　　Objective: To find important biomarkers through serum metabolites to study the cause of cardiac hypertrophy in rats.

　　Method: The rat cardiac hypertrophy model was established by intraperitoneal injection of 30 mg/(kg·D) isoproterenol for 30 consecutive days. The heart mass index is used to evaluate the rat cardiac hypertrophy model. Ultra performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry analysis is used to detect endogenous metabolites in rat serum, MPP software is used to analyze metabolite differences, HumanMetabolomeDatabase (HMDB) uses a database to determine biomarkers, and uses MetaboAnalyst 4.0 Analyze metabolic pathways.

　　Result: Intraperitoneal injection of isoproterenol can induce cardiac hypertrophy in rats. There are significant differences in serum metabolites between the cardiac hypertrophy model group and the normal group, and a total of 10 potential biomarkers have been identified. Compared with the normal group, the myocardial hypertrophy model group's sphingosine-1-phosphate and dihomo-γ-linolenic acid were significantly down-regulated, D-fluorofructose-1,6-diphosphate, deoxyadenosine,- Acetylmethionine, phytosphingosine, allantoin, 3-keto-β-D-galactose, octane number and glycerol were all significantly up-regulated.

　　Conclusion: Isoprene-induced cardiac hypertrophy includes metabolic pathways, such as sphingolipid metabolism, glycerolipid metabolism, galactose metabolism, unsaturated fatty acid biosynthesis and purine metabolism. This study provides a reference for revealing the changes in circulating blood metabolism in cardiac hypertrophy induced by isoproterenol.